Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Nucana Plc ADR (NCNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 367,724
  • Shares Outstanding, K 31,811
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,750 K
  • 36-Month Beta 4.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.20
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.22
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.37 +11.48%
on 02/08/19
16.20 -28.64%
on 01/23/19
-4.46 (-27.84%)
since 01/18/19
3-Month
10.37 +11.48%
on 02/08/19
19.90 -41.91%
on 11/30/18
-6.11 (-34.58%)
since 11/21/18
52-Week
10.37 +11.48%
on 02/08/19
32.00 -63.87%
on 06/07/18
-8.71 (-42.97%)
since 02/21/18

Most Recent Stories

More News
NuCana plc Announces Withdrawal of Public Offering of ADSs

EDINBURGH, United Kingdom, Jan. 25, 2019 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company (the "Company") focused on significantly improving treatment outcomes...

NCNA : 11.56 (-0.86%)
NuCana plc Announces Proposed Public Offering of ADSs

EDINBURGH, United Kingdom, Jan. 23, 2019 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with...

NCNA : 11.56 (-0.86%)
Amarin Down on Lower '19 View, Posts Preliminary '18 Results

Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.

AMRN : 17.43 (+1.34%)
MRUS : 11.20 (+0.36%)
NCNA : 11.56 (-0.86%)
MBRX : 1.37 (+3.01%)
Four Biotech Stocks That Popped More Than 50% in 2018

Four Biotech Stocks That Popped More Than 50% in 2018

GHDX : 78.35 (-6.35%)
VCEL : 19.19 (-0.93%)
NCNA : 11.56 (-0.86%)
VNDA : 20.03 (-1.62%)
NuCana to Participate in Citi's 2018 Global Healthcare Conference

EDINBURGH, United Kingdom, Nov. 28, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with...

NCNA : 11.56 (-0.86%)
NuCana Reports Third Quarter 2018 Financial Results and Provides Business Update

Favorable Data Presented at ESMO on NUC-1031 (Acelarin(R)) and NUC-3373

NCNA : 11.56 (-0.86%)
NuCana to Participate in the 2018 Evercore ISI HealthCONx Conference

EDINBURGH, United Kingdom, Nov. 20, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients,...

NCNA : 11.56 (-0.86%)
NuCana to Participate in the Jefferies 2018 London Healthcare Conference

EDINBURGH, United Kingdom, Nov. 07, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients,...

NCNA : 11.56 (-0.86%)
NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer

NuTide:302 Study Will Evaluate NUC-3373 in Combination with Other Agents Typically Administered with 5-FU

NCNA : 11.56 (-0.86%)
NuCana Sees Hammer Chart Pattern: Time to Buy?

NuCana PLC has been struggling lately, but the selling pressure may be coming to an end soon.

NCNA : 11.56 (-0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade NCNA with:

Business Summary

NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in...

See More

Key Turning Points

2nd Resistance Point 12.09
1st Resistance Point 11.82
Last Price 11.56
1st Support Level 11.42
2nd Support Level 11.29

See More

52-Week High 32.00
Fibonacci 61.8% 23.74
Fibonacci 50% 21.18
Fibonacci 38.2% 18.63
Last Price 11.56
52-Week Low 10.37

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar